ski, zeb2, meox2, and cardiac fibroblast phenotype · ian m.c. dixon, phd, fiacs 17 ... mesenchyme...
TRANSCRIPT
The Ski/Zeb2/Meox2 pathway provides a novel mechanism for regulation of the cardiac 1myofibroblast phenotype 2
3
Ryan H. Cunnington1,3†, Josette M. Northcott 2,3†, Saeid Ghavami 1,3, Krista L. Bathe 1,3, 4Fahmida Jahan2,3, Morvarid Kavosh1,3, Jared Davies1,3, Jeffrey T. Wigle 2,3, and Ian M.C. 5
Dixon1,3* 6
1Department of Physiology, University of Manitoba; 2Department of Biochemistry and Medical 7Genetics and 3 Institute of Cardiovascular Sciences University of Manitoba, Winnipeg, Canada 8
Running title: Ski, Zeb2, Meox2, and cardiac fibroblast phenotype 9 10
Word count: ~7428 11 12
† Co-first authorship 13*Address for correspondence: 14 15Ian M.C. Dixon, PhD, FIACS 16Professor of Physiology 17Director, Molecular Cardiology Lab 18Institute of Cardiovascular Sciences 19St. Boniface Research Centre 20351 Tache Avenue 21Winnipeg, Manitoba, Canada 22R2H 2A6 23 [email protected] 25www.sbrc.ca 26 27 28 29 30
31
© 2013. Published by The Company of Biologists Ltd.Jo
urna
l of C
ell S
cien
ceA
ccep
ted
man
uscr
ipt
JCS Advance Online Article. Posted on 23 October 2013
Summary 32
Background: Cardiac fibrosis is linked to fibroblast to myofibroblast phenoconversion and 33
proliferation; mechanisms underlying this phenoconversion are poorly understood. c-Ski (Ski) is 34
a negative regulator of TGF-β/Smad signaling in myofibroblasts, and may redirect the 35
myofibroblast phenotype back to fibroblasts. Meox2 may alter TGF-β-mediated cellular 36
processes and is repressed by Zeb2. Hypothesis: Ski diminishes the myofibroblast phenotype by 37
de-repressing Meox2 expression and function via repression of Zeb2 expression. Results: Meox1 38
and Meox2 mRNA expression, Meox2 protein expression are reduced during phenoconversion 39
of fibroblasts to myofibroblasts. Meox2 over-expression shifts the myofibroblasts to fibroblasts, 40
whereas the Meox2 DNA-binding mutant has no effect on myofibroblast phenotype. Ski over-41
expression partially restores Meox2 mRNA expression levels to those in cardiac fibroblasts. 42
Expression of Zeb2 increased during phenoconversion and Ski over-expression reduces Zeb2 43
expression in first-passage myofibroblasts. Meox2 expression is decreased in scar following 44
myocardial infarction, whereas Zeb2 protein expression increases in the infarct scar. Thus Ski 45
modulates the cardiac myofibroblast phenotype and function via suppression of Zeb2 by up-46
regulating Meox2. This cascade may regulate cardiac myofibroblast phenotype and presents 47
therapeutic options for treatment of cardiac fibrosis. 48
49
Keywords: myofibroblasts; heart; phenoptype switch; fibrosis; TGF-β50
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Introduction 51
Fibroblast to myofibroblast phenoconversion in the heart is a critical event in the onset of many 52
cardiovascular diseases. Cardiac fibroblasts are an understudied cell despite the fact that they 53
constitute the majority of cells in the heart (Weber and Brilla, 1991). These relatively quiescent 54
cells reside in the cardiac interstitium and synthesize cardiac fibrillar collagen types (e.g., types I 55
and III), as well as the majority of other extracellular matrix proteins. 56
Cardiac stress and injury both induce differentiation of fibroblasts into hypersecretory 57
and contractile myofibroblasts which can persist in the myocardium for months (and even years) 58
after the initial pathological insult (Willems et al., 1994). The myofibroblast is associated with 59
fibrillar collagen deposition leading to reduced cardiac efficiency and, ultimately, 60
decompensated heart failure. Initially, increased collagen deposition is beneficial, but when left 61
to persist for years, it may transform healthy myocardium with normal extracellular matrix 62
complement to overtly fibrosed tissue with abnormal expansion of the interstitium (Freed et al., 63
2005). 64
Fibroblast-to-myofibroblast phenoconversion is marked by increased expression of α-65
smooth muscle actin (α-SMA) (Darby et al., 1990), extra domain A (ED-A) fibronectin (Serini et 66
al., 1998), and non-muscle myosin heavy chain b (SMemb) (Frangogiannis et al., 2000). 67
Although not well understood, this process is typically thought of as being a “one-way” pathway. 68
However, Hinz and colleagues have provided data that both forward and reverse 69
phenoconversion are possible in these cells depending upon the compressibility of the underlying 70
substrate (Hinz et al., 2001). Still, the molecular mechanisms for fibroblast/myofibroblast inter-71
conversion have yet to be fully elucidated. 72
The canonical TGF-β signaling cascade has been implicated as an important inducer of 73
phenoconversion. High levels of this cytokine are associated with cardiac fibrosis (Brooks and 74
Conrad). The diverse functions of TGF-β necessitate the tight control of membrane-to-nucleus 75
signal transduction; in particular, levels of the endogenous inhibitors Smad7 and Ski. The proto-76
oncoprotein Ski has a complex set of functions and is linked to skeletal muscle hypertrophy 77
(Sutrave et al., 1990a; Sutrave et al., 1990b), as well as developmental defects in the neural tube 78
and cranial mesenchyme (Berk et al., 1997). Ski binds to R-Smads (Sun et al., 1999; Suzuki et 79
al., 2004; Ueki and Hayman, 2003; Xu et al., 2000) and may inhibit TGF-β mediated effects 80
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
through both nuclear and cytosolic mechanisms (Akiyoshi et al., 1999; Ferrand et al., 2010; 81
Nagata et al., 2006; Suzuki et al., 2004). We have previously demonstrated the anti-fibrotic and 82
anti-contractile effects of Ski over-expression in TGF-β1 stimulated primary cardiac 83
myofibroblasts, and have shown these inhibitory effects to be orchestrated at the nuclear level 84
(Cunnington et al., 2011). 85
Mesenchyme homeobox 2 (Meox2, also known as growth arrest specific homeobox 86
protein, Gax) and Meox1 comprise the Meox family of homeodomain proteins. Meox1 and 87
Meox2 proteins share 95% sequence identity within the homeodomain region, but are otherwise 88
highly divergent (Douville et al., 2011). Both Meox1 and Meox2 are required for proper bone 89
and muscle formation in developing mouse embryos (Mankoo et al., 1999; Mankoo et al., 2003). 90
Meox2 expression is decreased by mitogen stimulation of vascular smooth muscle cells (Gorski 91
et al., 1993) and in mechanically damaged arteries (Weir et al., 1995), indicating that Meox2 92
expression is sensitive to a range of stimuli. Meox2 may enhance TGF-β mediated inhibition of 93
cell proliferation (Valcourt et al., 2007) or, conversely, may block TGF-β induced epithelial-to-94
mesenchymal transition (EMT) (Valcourt et al., 2007). Meox2 expression is repressed by the 95
Zeb2 protein (also called Smad interacting protein 1 (Sip1 or Zfhx1b)), a zinc-finger E-box 96
binding protein (Chen et al., 2010). Zeb2 expression itself has been shown to be positively 97
regulated by TGF-β signaling during EMT (Comijn et al., 2001). 98
In this study we provide data to support a novel mechanism through which Ski regulates 99
the cardiac fibroblast phenotype. We show for the first time that both Meox1 and Meox2 are 100
down-regulated during fibroblast to myofibroblast phenoconversion, and that over-expression of 101
Ski can rescue Meox2 expression. Moreover, our data establish a link between increased Meox2 102
expression and diminution of the myofibroblast phenotype. Finally, we identify a putative 103
signaling cascade that may modulate fibroblast to myofibroblast phenoconversion through the 104
differential expression of Ski, Zeb2 and Meox2 proteins. 105
106
Results 107
Meox1 and Meox2 are down-regulated during phenoconversion – Marker proteins frequently 108
used to monitor fibroblast-to-myofibroblast phenoconversion include an increase in expression 109
of α-SMA (Darby et al., 1990), ED-A fibronectin (Serini et al., 1998) and SMemb 110
(Frangogiannis et al., 2000). Myofibroblasts in the infarct scar may arise from a range of 111
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
different processes, e.g., fibroblast migration (Gabbiani, 1996), differentiation of bone marrow 112
progenitor cells (Mollmann et al., 2006; van Amerongen et al., 2008) and EMT (van Tuyn et al., 113
2007; Zhou et al., 2010). As Meox2 is associated with inhibition of TGF-β1 induced EMT 114
(Valcourt et al., 2007), we examined the potential link between Meox2 and induction of the 115
myofibroblast phenotype in rat primary cardiac fibroblasts, and in first and second passage 116
myofibroblasts. To our knowledge, Meox1, closely related to Meox2, has not been implicated in 117
EMT or TGF-β1 signaling. Therefore we also examined its putative role in fibroblast to 118
myofibroblast phenoconversion. We observed a 96 and 99% down-regulation of Meox2 mRNA 119
expression during the phenoconversion (Figure 1A) of primary fibroblasts (P0) to first and 120
second passage myofibroblasts (P1 and P2), respectively. Meox1 mRNA decreased with 121
increasing passage in an identical manner to that of Meox2 (Figure 1A). Western analysis 122
demonstrated that Meox2 protein expression is also significantly decreased during fibroblast to 123
myofibroblast phenoconversion (Figure 1B). 124
Meox2 expression is decreased in post-myocardial infarct (post-MI) scar – To assess the 125
relevance of Meox2 expression to myofibroblast phenotype in vivo, we performed 126
immunohistochemistry on 4 week post-MI hearts (Figure 1C). Vimentin staining (red color in 127
composite) intensity was increased in the infarct scar region showing the predominance of 128
mesenchymal cells (e.g., myofibroblasts) in the infarct scar. We observed a substantial reduction 129
in Meox2 staining (green color in composite) in the scar portion of the heart compared to the 130
remnant heart. Nuclei were stained with DAPI (blue color). 131
Meox2, but not Meox1, over-expression diminishes the myofibroblast phenotype – As Meox1 and 132
Meox2 mRNA expression is down-regulated during fibroblast-to-myofibroblast differentiation, 133
we hypothesized that re-introduction of these proteins in first passage myofibroblasts would 134
restore the fibroblastic phenotype. Using an adenoviral system for over-expression of Meox1 and 135
Meox2, we observed that Meox2 was able to reduce the expression of the myofibroblast markers 136
α-SMA and ED-A fibronectin (Figure 2A and 2B). In contrast, Meox1 had no effect on 137
expression of these markers (Figure 2). Notably, over-expression of Meox1 or Meox2 did not 138
affect SMemb expression (Figure 2). Finally, over-expression of a DNA binding deficient 139
version of Meox2 (Meox2DBDmt) (Douville et al., 2011) was unable to alter the myofibroblast 140
phenotype (Figure 2C and 2D). 141
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Meox2 over-expression induces myofibroblast proliferation - We have previously shown that 142
Meox2 expression induces cell cycle arrest and senescence in vascular endothelial cells 143
(Douville et al., 2011). However, in cardiac myofibroblasts, Meox2 over-expression induces 144
significant (p <0.01, p < 0.001) proliferation (Figure 3) indicating that Meox2-mediated effects 145
on cellular proliferation are cell type dependent. 146
Ski diminishes, but does not fully reverse, the myofibroblast phenotype - Our lab has previously 147
shown the ability of Ski over-expression to diminish expression of the myofibroblast phenotypic 148
marker α-SMA in first passage myofibroblasts (Cunnington et al., 2011). To extend this finding, 149
we tested the expression of additional markers of phenoconversion by Western analysis. 150
Following Ad-Ski transduction for 24 hours, we observed that Ski over-expression was able to 151
significantly reduce ED-A fibronectin expression, yet had no effect on the expression of SMemb 152
(Figure 4), as we had observed following over-expression of Meox2 (Figure 1C and 1D). Thus, 153
while the fibroblastic phenotype was not fully restored, the myofibroblastic phenotype was 154
significantly diminished. 155
Ski increases Meox2, but not Meox1, mRNA expression – Given the identical effects of Ski and 156
Meox2 over-expression on diminution of the myofibroblast phenotype, we hypothesized that a 157
link may exist between these two proteins. We therefore transduced first passage cardiac 158
myofibroblasts with Ad-Ski and then measured the mRNA expression levels of Meox1 and 159
Meox2 with and without TGF-β1 stimulation (10 ng/ml for 24 h). In the absence of TGF-β1 160
stimulation, Ad-Ski over-expression resulted in a ~5.5 fold increase in Meox2 mRNA expression 161
levels over controls, but produced no discernible effect on Meox1 levels (Figure 5). Following 162
TGF-β1 stimulation, Meox1 mRNA levels were, again, unaltered, whereas those of Meox2 163
increased ~7.5 fold above control levels. However, this increase was not found to be 164
significantly different when compared with the Meox2 levels attained by Ad-Ski over-expression 165
in the absence of TGF-β1 stimulation (Figure 5). 166
Zeb2 expression increases during fibroblast-to-myofibroblast differentiation – As down-167
regulation of Meox2 mRNA and protein is associated with phenoconversion, we examined the 168
potential role of Zeb2 (a repressor of Meox2 transcription), in fibroblast-to-myofibroblast 169
differentiation. Proteins were isolated from primary cardiac fibroblasts and first and second 170
passage myofibroblasts and tested for Zeb2 protein expression. We observed a significant up-171
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
regulation of Zeb2 protein in P1 and P2 myofibroblasts as compared to primary fibroblasts 172
(Figure 6A, C). 173
Over-expression of Ski reduces Zeb2 expression – Since the Zeb2 protein has been shown to 174
repress Meox2 expression in human umbilical vein endothelial cells (Chen et al., 2010), we 175
examined Ski over-expressing cells for Zeb2 protein expression. Following 48 hours of 176
incubation with Ad-Ski, we observed a significant reduction in Zeb2 protein expression, as 177
compared with non-transduced and Ad-LacZ transduced P1 myofibroblasts (Figure 6 B, D). 178
These data provide a link between Ski, Zeb2 and Meox2 expression levels in modulating cardiac 179
fibroblast/myofibroblast phenotype. 180
Meox2 decreases while Zeb2 increases in cytoplasm following myocardial infarction (MI)-We 181
have previously shown that Ski accumulates in the cytoplasm after myocardial infarction 182
(Cunnington et al., 2011). We examined Meox2 and Zeb2 expression in an in vivo coronary 183
ligation model of MI. We observed a significant decrease in Meox2 expression in the cytosolic 184
fraction at 48 h and 4 weeks post-MI scar portion of the heart as compared to sham and viable 185
tissue. While expression of Meox2 at 2 weeks post-MI also decreased in the scar, the change was 186
not significant (Figure 7). Zeb2 expression was significantly increased in the cytosolic fractions 187
48 h and 2 weeks post-MI, but was decreased at 4 weeks post-MI in the scar portion of the heart 188
compared with sham heart and viable tissue (Figure 7). 189
Discussion 190
Cardiac fibroblast-to-myofibroblast phenoconversion constitutes an important area of 191
investigation due to the long-term deleterious consequences of chronic fibrosis in the heart. 192
However, the mechanism(s) by which this phenomenon occurs is/are poorly understood. 193
Myofibroblasts arise in the heart in response to the stress/injury associated with MI, 194
hypertension, diabetic cardiomyopathy, as well as other cardiomyopathies (Gonzalez-Vilchez et 195
al., 2005; Gonzalez et al., 2002; Ihm et al., 2007; Pelouch et al., 1993). These cells contribute to 196
inappropriate myocardial remodeling that is characterized by the deposition of excessive fibrillar 197
collagens which impair overall cardiac function and hasten the progression into heart failure. 198
Myofibroblasts persist in the injured heart for years (Willems et al., 1994) and the mechanism for 199
the rescue of the quiescent fibroblastic phenotype in vivo has yet to be determined. 200
The importance of mechanical tension in regulating fibroblast/myofibroblast 201
differentiation has been shown in vitro and in vivo (Hinz et al., 2001) (Wang et al., 2003); (Arora 202
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
et al., 1999). Others have also identified stretch as being a modulator of myofibroblast phenotype 203
(Thayer et al., 2011). Additional factors have been shown to affect myofibroblast phenotype, for 204
example Wnt3a signaling (Carthy et al., 2011). Knowledge of the precise mechanisms mediating 205
this process is vital to creating an effective treatment for fibrotic diseases of the heart. 206
In this study, we have identified a novel signaling pathway that regulates the 207
differentiation of primary cardiac fibroblasts to myofibroblasts (Figure 8), and highlights the 208
involvement of three proteins that are associated with phenoconversion, namely, Ski, Meox2 and 209
Zeb2. Herein we provide evidence that Ski de-represses Meox2 via repression of Zeb2 to reduce 210
the myofibroblast phenotype (i.e., α-SMA and ED-A fibronectin expression) and, taken with our 211
previous study (Cunnington et al., 2011) thereby reduces collagen synthesis/secretion and 212
contracture. 213
Figure 3 provides evidence that Meox2 overexpression induces cardiac myofibroblast 214
proliferation. We postulate that the finding of decreasing myofibroblast marker expression does 215
not reflect a hypoproliferation of cells. Rather, this indicates the decreased averaged expression 216
of cardiac myofibroblast markers from each cell en masse. Seminal work by Gabbiani and 217
colleagues has led to the well accepted tenet that transition from so-called fibroblastic phenotype 218
to a differentiated supermature myofibroblast is not defined as an on/off event, but is a 219
continuum (Desmouliere et al., 2005). Thus one may observe altered expression of salient 220
markers and proliferative capacity in cells that retain the relative contractility and hypersecretory 221
characteristics of myofibroblasts. While they may not be supermature myofibroblasts, they 222
retain high expression of the specific markers. While Gabbiani et al carried out their work 223
largely in skin myofibroblasts, we have extended this work to cardiac myofibroblasts with the 224
work of (Santiago et al., 2010) which showed a similarly detailed graded expression of 225
myofibroblastic markers both in vivo and in vitro. Further, in our studies on Ski (Cunnington et 226
al., 2011) we found that Ski acts a molecular rheostat to “dial back” the expression of salient 227
markers for myofibroblasts in these cells. Thus, we interpret Figure 3 results to represent 228
increased proliferation of a population with an intermediate phenotype, still categorized as 229
myofibroblasts. 230
In addition to the changes in protein levels typically observed with the more commonly 231
used indicators of fibroblast-to-myofibroblast phenoconversion (i.e., α-SMA, ED-A fibronectin, 232
and SMemb) (Darby et al., 1990; Frangogiannis et al., 2000; Serini et al., 1998), we show that 233
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Meox1 and Meox2 mRNA levels are down-regulated during phenoconversion. Our observation 234
that a loss of Meox2 protein is associated with phenoconversion suggests they may be important 235
in maintaining the quiescent phenotype. Moreover, increased Zeb2 protein expression, associated 236
with increasing passage number, points to a direct molecular mechanism for the down-regulation 237
of Meox2 and subsequent change in cellular phenotype. Thus, Meox2 and Zeb2 form part of a 238
signal cascade that is regulated by Ski, and drives the differentiation of fibroblasts into 239
hypersynthetic myofibroblasts (Figure 8). Although fibroblast-to-myofibroblast phenoconversion 240
is a complex process that likely requires a myriad of signals to proceed, our current results shed 241
light on the nature of these pathways. 242
If treatment of primary cells with Ski or Meox2 adenoviruses were enriching a fibroblast 243
population (as opposed to reducing myofibroblast phenotype) then the expected result would be 244
a decrease in all myofibroblast markers. Our results do show a decrease in alpha-SMA and ED-A 245
fibronectin, but do not show a significant change in SMemb (a third myofibroblast marker). We 246
interpret this result to indicate a diminution of the myofibroblast cell phenotype rather than an 247
enrichment of a fibroblast sub-population. 248
Ad-Ski or Ad-Meox2 transduction was able to partially reverse the myofibroblastic 249
phenotype as indicated by a reduction in α-SMA and ED-A fibronectin expression levels. 250
However, exogenous application of these two proteins could not fully restore the fibroblastic 251
phenotype as characterized by steady levels of SMemb. Thus, we interpret this finding as 252
indicating that the cells convert to a proto-myofibroblastic phenotype. Although Meox1 and 253
Meox2 share a high degree of amino acid sequence identity within their homeodomains, they are 254
otherwise quite divergent from each other (Douville et al., 2011). Therefore, the observation that 255
Meox1and Meox2 did not exert the same effects on P1 myofibroblasts was not necessarily 256
surprising. Meox1 mRNA expression was dramatically reduced in first passage myofibroblasts 257
as compared to primary fibroblasts. However, over-expression of this protein did not modulate 258
the expression of any of the myofibroblastic phenotype markers analyzed. However, Meox1 may 259
affect the expression of other proteins related to phenoconversion that were not examined in this 260
study. Alternatively, Meox1 may not directly affect fibroblast/myofibroblast phenotype at all, but 261
is simply down-regulated as a “side effect” of other mechanisms operating during the process of 262
phenoconversion. The DNA binding deficient version of Meox2, Meox2DBDmt, was also 263
unable to elicit changes in myofibroblast phenotype, indicating that an interaction of Meox2 with 264
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
DNA is necessary to alter the gene expression patterns that are essential for a diminished 265
myofibroblastic phenotype. The mechanism of these changes is currently unknown. 266
We found that Ski, Meox2 and Zeb2 are relatively unregulated in viable eg, noninfarcted 267
tissues at various times following myocardial infarction, and that regulation is significant in the 268
infarct scar in the viable region with these three genes at many of the times assessed in the data 269
from these two different papers. As we know that the infarct scar is populated mainly by 270
myofibroblasts in the infarct scar (Santiago et al., 2010), and the viable cardiac tissue is 271
composed of at least 4 different cell types including cardiac myocytes, we expect the diversity of 272
cell types may be at the basis of this disparity between regions. This cumulative finding may 273
also point to the existence of another regulatory network specific to the viable region. 274
In subcellular fractionation experiments designed to detect cytosolic Meox2, we observed 275
a significant reduction of expression in early (48 hr) and late (4 weeks) time points following 276
myocardial infarction (Figure 7). In contrast, Zeb2 was significantly elevated in early (48 hr and 277
2 weeks post-myocardial infarction) and reduced in late stage (4 weeks post-myocardial 278
infarction) relative to sham-operated and viable sample averages . These contrasting expression 279
patterns are consistent with our model of signaling response following myocardial injury (Figure 280
8). Further, our immunofluorescence data of infarcted rat heart revealed a striking relative 281
reduction of Meox2 (Figure 1C), which may underscore the pathophysiological relevance of this 282
pathway in this model of human heart disease, as the infarct scar is populated by myofibroblasts 283
(Santiago et al., 2010). 284
In the infarct scar, we found evidence for elevated cytosolic Zeb2. This finding may 285
point to a new mechanism for Zeb2-mediated regulation of Meox2. For example, Zeb2 could be 286
decreasing Meox2 indirectly via sequestration to the cytoplasm of transcriptional activators of 287
Meox2 expression, much as C184M sequesters receptor-activated Smad2 (Kokura et al., 2003). 288
The elucidation of this possible regulatory mode will be an object of our future studies. 289
We have previously shown that Ski expression increases as fibroblasts phenoconvert into 290
myofibroblasts, both in culture and during cardiac remodeling following myocardial infarction 291
(Cunnington et al., 2011). This result may seem counter intuitive in relation to the observed 292
effect of exogenous Ski application decreasing Zeb2 expression and diminishing the 293
myofibroblast phenotype. However, in the infarct scar, Ski localization shifts from nuclear to 294
cytoplasmic during the progression of cardiac remodeling and the associated fibroblast-to-295
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
myofibroblast phenoconversion (Cunnington et al., 2011). Ad-Ski localizes to the nucleus and 296
causes diminution of myofibroblast phenotype. Thus, Ski localization is important in 297
determining its function. Within the nucleus, we propose that Ski, via inhibiting Smad signaling, 298
inhibits Zeb2 production thus maintaining an elevated level of Meox2 that helps to keep the 299
fibroblast in a quiescent state. When Ski translocates to the cytosol, however, the mechanisms 300
required to maintain the quiescent phenotype are disabled and the cell differentiates into a 301
myofibroblast. Thus, nuclear Ski may act as a cellular “brake” in preventing differentiation of 302
fibroblasts to myofibroblasts via its ability to inhibit Zeb2 expression, thereby relieving Zeb2's 303
inhibitory influence on Meox2 expression levels. In the damaged heart, however, that “brake” 304
may be released by the shuttling of Ski from the nucleus to the cytosol. 305
Understanding the specific mechanisms that orchestrate fibroblast-to-myofibroblast 306
phenoconversion is critical in developing effective strategies for the treatment of fibrotic heart 307
disease. The current results outline a novel signaling pathway that regulates phenoconversion 308
between cardiac fibroblasts and myofibroblasts. 309
310
Materials and Methods 311
Cell isolation/culture: Cardiac fibroblasts were isolated as described previously (Hao et al., 312
2000). Briefly, hearts from adult male Sprague-Dawley rats (150-200g) were subjected to 313
Langendorff perfusion with DMEM-F12 (Gibco, Carlsbad, CA, USA) followed by SMEM 314
(Gibco, Carlsbad, CA, USA). Perfused hearts were digested with 0.1% w/v collagenase type 2 315
(Worthington) in SMEM for 20 minutes, removed from the Langendorff apparatus, and 316
minced/triturated in dilute collagenase solution (0.05% w/v) for 15 minutes before addition of 317
growth media (DMEM-F12 supplemented with 10% fetal bovine serum (FBS), 100 U/ml 318
penicillin (Gibco BRL), 100 µg/ml streptomycin (Gibco, Carlsbad, CA, USA), and 1 µM 319
ascorbic acid (Sigma-Aldrich, St. Louis, MO, USA)). Upon settling of large tissue pieces in a 50 320
ml conical tube, the supernatant was recovered and centrifuged at 750 x g for 5 minutes. Cell 321
pellets were resuspended in growth media and plated in 75 cm2 culture flasks. Cells were 322
allowed to adhere for 2-3 hours in a 5% CO2 37oC incubator, then washed twice with phosphate-323
buffered saline (PBS) followed by the addition of fresh growth media. The media was changed 324
the following day and cells allowed to grow for 3-4 days before passaging into P1 325
myofibroblasts. P1 myofibroblasts were infected with adenovirus at the time of plating. 326
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Transforming growth factor beta 1 (TGF-β1) cytokine (Cell Signaling, Danvers, MA, USA) (10 327
ng/ml) treatment was applied to cells following a 24 hr period of serum starvation. 328
Adenoviral constructs: Generation of the HA-Ski adenoviral vector was previously described 329
(Cunnington et al., 2011). Construction of the Meox1, Meox2 and Meox2 DNA binding deficient 330
adenoviruses (Meox2DBDmt) was previously described (Douville et al., 2011). 331
Protein isolation: Following treatment, cells were washed twice with PBS. RIPA lysis buffer 332
containing protease inhibitor cocktail (Sigma, St. Louis, MO, USA) and phosphatase inhibitors 333
(10 mmol/L NaF, 1 mmol/L sodium orthovanadate, and 20 mmol/L β-glycorophosphate) was 334
used to lyse cells and, following mechanical scraping, cell lysates were incubated on ice for 1 335
hour. Lysates were sonicated for 3 x 10 seconds and then centrifuged at 8765 x g at 4oC for 15 336
minutes. Supernatants were transferred to new tubes and protein assays performed using the 337
bicinchoninic acid method (Smith et al., 1985). 338
Western Blot analysis: SDS-PAGE of 20-40 ug of protein was performed on 6-8% gels using 339
SeeBlue Plus2 Pre-Stained Standard (BioRad, Hercules, CA, USA) molecular weight marker. 340
Proteins were transferred to 0.45 µM polyvinylidene difluoride (PVDF) membrane and blocked 341
in PBS with 0.2% Tween-20 (PBS-T) containing 10% skim milk for 1.5 hours at room 342
temperature with constant shaking. Primary antibodies were diluted in PBS-T with 3% skim milk 343
as follows: Zeb2 (1:1,000) (Sigma, St. Louis, MO, USA), β-tubulin (1:5,000) (Abcam, 344
Cambridge, UK), α-smooth muscle actin (1:5,000) (Sigma, St. Louis, MO, USA), eukaryotic 345
elongation factor 2 (eEF2) (1:3,000) (Cell Signaling, Danvers, MA, USA), ED-A fibronectin 346
(1:1,000) (Chemicon, Temecula, CA, USA), SMemb (1:1,000) (Abcam, Cambridge, UK), FLAG 347
[M2] (1:10,000) (Sigma, St. Louis, MO, USA), Meox2 [JJ-7] (1:1000) (Santa Cruz 348
Biotechnology. Santa Cruz, CA, USA), α-tubulin (1:2000) (Abcam, Cambridge, UK). 349
Membranes were incubated for 1.5 hours at room temperature or overnight at 4oC with shaking. 350
Secondary antibodies were horseradish peroxidase (HRP)-labeled anti-rabbit and HRP-labeled 351
anti-mouse antibodies, which were diluted 1:10,000 with PBS-T with 3% skim milk and 352
incubated for 1.5 hours at room temperature with shaking. Protein bands were visualized using 353
ECL or ECL Plus (Amersham, Arlington Heights, IL, USA) according to the manufacturer's 354
instructions, and developed on X-ray film. Equal protein loading was confirmed using β-tubulin , 355
α-tubulin or eEF2 staining following stripping and re-probing of the Western blots. 356
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
RNA isolation: Cardiac fibroblasts/myofibroblasts in 100 mm dishes were harvested for RNA 357
using GenElute Mammalian Total RNA miniprep kits (Sigma, St. Louis, MO, USA) or RNeasy 358
Plus kits (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. RNA was 359
diluted in 10 mM Tris (pH 7.5) and the absorbance at 260 nm (A260) was used to determine RNA 360
concentration. RNA purity was assessed using the ratio of absorbance at 260 nm to absorbance at 361
280 nm (A260/A280). 362
qPCR: Isolated RNA was treated with RQ1 RNase-Free DNase according to the manufacturer’s 363
instructions. One-step real-time PCR was performed using an iQ5 thermocycler (BioRad, 364
Hercules, CA, USA) and BR 1-Step SYBR Green qRT-PCR kits (Quanta, Gaithersburg, MD, 365
USA). Relative gene quantification (2-ΔΔCT method) was performed whereby the mRNA 366
expression levels of Meox1 and Meox2 were compared to the mRNA expression of GAPDH. 367
Primer sets for Meox1(amplicon = 123 bp): ratMEOX1forward - 5'-tcgcccaccataactacctg-3', 368
ratMEOX1reverse - 5'-ccttcacacgcttccacttc-3'; Meox2 (amplicon = 114 bp): ratMEOX2forward - 369
5'-ttagcgggctctgctcaaac-3', ratMEOX2reverse - 5'-ttcacgaaggtcccaaagtc-3'; GAPDH (amplicon = 370
87 bp): GAPDH forward - 5’-tgcaccaccaactgcttagc-3’, GAPDH reverse - 5’-371
ggcatggactgtggtcatgag-3’. Parameters for qPCR amplification steps available upon request. 372
EdU cell proliferation assay: P3 myofibroblasts (40% confluent) were infected with Meox2 and 373
LacZ adenovirus (50 and 100 MOI). Click-iT™ EdU flow cytometry assay kit (Invitrogen,) was 374
used to further investigate Meox2 effects on primary rat myofibroblast proliferation. Briefly, 5-375
ethynyl-2´-deoxyuridine (EdU) reagent was added at a 10 µM concentration 16 after infection 376
and cells were harvested 8 h later. Cells were collected, fixed and then incubated with saponin-377
based permeabilization buffer. Click-iT reaction cocktail containing copper sulphate and 378
fluorescent dye azide (Alexa Fluor® 488) was freshly prepared and added to the samples. EdU 379
incorporation into DNA was assessed using flow cytometry. Simultaneously, cells were counted 380
using a hemocytometer to confirm the EdU FACS assay (Hesam Movassagh et al., 2013; In 381
press). 382
Experimental rat model of MI and cellular fractionation: Experimental protocols for animal 383
studies were approved by the Animal Care Committee of the University of Manitoba, Canada, 384
and conform to the guidelines established by the Canadian Institutes of Health Research and the 385
Canadian Council on Animal Care (2001). MI was induced in male Sprague-Dawley rats (150–386
175 g) by surgical occlusion of the left coronary artery, as described previously (Dixon et al., 387
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
1990). The mortality of the animals operated on in this fashion was 30% within 48 hr. 388
Experimental animals were sacrificed after 48 hr (i.e., acutely-infarcted), and 2 or 4 weeks (i.e., 389
chronically-infarcted) post-MI, and cardiac tissues isolated from two, left ventricular (LV) 390
regions: remnant/viable (i.e., non-infarcted) LV free wall remote from the infarct scar and 391
septum), and infarct scar. Infarcted (i.e., pale, necrotic tissue in acutely-infarcted vs. overtly-392
healed scar tissue in chronically-infarcted animals) and non-infarcted regions were determined 393
visually, and compared with the same regions obtained from sham-operated rats. Cardiac tissues 394
from sham-operated LVs, viable LVs, and scar regions were homogenized in 100 mM Tris (pH 395
7.4) containing 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 4 µM leupeptin, 1 µM 396
pepstatin, 0.3 µM aprotinin. This homogenate was sonicated for 5 x 5 seconds. To isolate the 397
cytosolic fractions, the samples were centrifuged at 3000 x g for 10 min at 4 °C. The resulting 398
supernatant was further subjected to centrifugation at 48000 x g for 20 min at 4°C (Cunnington 399
et al., 2011). The resulting supernatant was used for the cytosolic Meox2 and Zeb2 protein 400
assays by Western blot. 401
402
Statistics. Data were analyzed using SigmaStat software and are expressed as mean ± SEM. 403
Groups were compared using one-way ANOVA with Student-Newman-Keuls post hoc test for 404
multiple group comparisons. * indicates P < 0.05 unless otherwise indicated. 405
406
Acknowledgements This work was supported by the Canadian Institutes for Health Research 407
(IMCD/JTW) and the Heart and Stroke Foundation of Manitoba (IMCD/JTW). JTW is a MHRC 408
Manitoba Research Chair. RHC is the recipient of the MHRC/CIHR RPP doctoral student 409
scholarship. SG is a Parker B. Francis scholar in Respiratory Diseases. 410
411
Disclosures None. 412
413
References 414
Akiyoshi, S., Inoue, H., Hanai, J., Kusanagi, K., Nemoto, N., Miyazono, K. and 415Kawabata, M. (1999). c-Ski acts as a transcriptional co-repressor in transforming growth factor-416beta signaling through interaction with smads. J Biol Chem 274, 35269-77. 417
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Arora, P. D., Narani, N. and McCulloch, C. A. (1999). The compliance of collagen 418gels regulates transforming growth factor-beta induction of alpha-smooth muscle actin in 419fibroblasts. Am J Pathol 154, 871-82. 420 Berk, M., Desai, S. Y., Heyman, H. C. and Colmenares, C. (1997). Mice lacking the 421ski proto-oncogene have defects in neurulation, craniofacial, patterning, and skeletal muscle 422development. Genes Dev. 11, 2029-2039. 423 Brooks, W. W. and Conrad, C. H. (2000). Myocardial fibrosis in transforming growth 424factor beta(1)heterozygous mice. Journal of molecular and cellular cardiology 32, 187-95. 425 Carthy, J. M., Garmaroudi, F. S., Luo, Z. and McManus, B. M. (2011). Wnt3a 426induces myofibroblast differentiation by upregulating TGF-beta signaling through SMAD2 in a 427beta-catenin-dependent manner. PLoS One 6, e19809. 428 Chen, Y., Banda, M., Speyer, C. L., Smith, J. S., Rabson, A. B. and Gorski, D. H. 429(2010). Regulation of the expression and activity of the antiangiogenic homeobox gene 430GAX/MEOX2 by ZEB2 and microRNA-221. Mol Cell Biol 30, 3902-13. 431 Comijn, J., Berx, G., Vermassen, P., Verschueren, K., van Grunsven, L., Bruyneel, 432E., Mareel, M., Huylebroeck, D. and van Roy, F. (2001). The two-handed E box binding zinc 433finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 7, 1267-78. 434 Cunnington, R. H., Wang, B., Ghavami, S., Bathe, K. L., Rattan, S. G. and Dixon, I. 435M. (2011). Antifibrotic properties of c-Ski and its regulation of cardiac myofibroblast phenotype 436and contractility. Am J Physiol Cell Physiol 300, C176-86. 437 Darby, I., Skalli, O. and Gabbiani, G. (1990). Alpha-smooth muscle actin is transiently 438expressed by myofibroblasts during experimental wound healing. Lab Invest 63, 21-9. 439 Desmouliere, A., Chaponnier, C. and Gabbiani, G. (2005). Tissue repair, contraction, 440and the myofibroblast. Wound Repair Regen 13, 7-12. 441 Dixon, I. M. C., Lee, S. L. and Dhalla, N. S. (1990). Nitrendipine binding in congestive 442heart failure due to myocardial infarction. Circ.Res. 66, 782-788. 443 Douville, J. M., Cheung, D. Y., Herbert, K. L., Moffatt, T. and Wigle, J. T. (2011). 444Mechanisms of MEOX1 and MEOX2 regulation of the cyclin dependent kinase inhibitors p21 445and p16 in vascular endothelial cells. PLoS One 6, e29099. 446 Ferrand, N., Atfi, A. and Prunier, C. (2010). The oncoprotein c-ski functions as a 447direct antagonist of the transforming growth factor-{beta} type I receptor. Cancer Res 70, 8457-44866. 449 Frangogiannis, N. G., Michael, L. H. and Entman, M. L. (2000). Myofibroblasts in 450reperfused myocardial infarcts express the embryonic form of smooth muscle myosin heavy 451chain (SMemb). Cardiovasc.Res 48, 89-100. 452 Freed, D. H., Cunnington, R. H., Dangerfield, A. L., Sutton, J. S. and Dixon, I. M. 453(2005). Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart. 454Cardiovasc.Res. 65, 782-792. 455 Gabbiani, G. (1996). The cellular derivation and the life span of the myofibroblast. 456Pathol Res Pract 192, 708-11. 457 Gonzalez-Vilchez, F., Ayuela, J., Ares, M., Pi, J., Castillo, L. and Martin-Duran, R. 458(2005). Oxidative stress and fibrosis in incipient myocardial dysfunction in type 2 diabetic 459patients. International journal of cardiology 101, 53-8. 460 Gonzalez, A., Lopez, B., Querejeta, R. and Diez, J. (2002). Regulation of myocardial 461fibrillar collagen by angiotensin II. A role in hypertensive heart disease? Journal of molecular 462and cellular cardiology 34, 1585-93. 463
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Gorski, D. H., LePage, D. F., Patel, C. V., Copeland, N. G., Jenkins, N. A. and 464Walsh, K. (1993). Molecular cloning of a diverged homeobox gene that is rapidly down-465regulated during the G0/G1 transition in vascular smooth muscle cells. Mol Cell Biol 13, 3722-46633. 467 Hao, J., Roth, J., Edmunds, L. H., Jr., Jones, S. C. and Dixon, I. M. C. (2000). 468Altered pattern of fibrosis and MMP activity in Kevlar patch stiffened acute myocardial 469infarction. Ann.Surg. manuscript in preparation. 470 Hesam Movassagh, M., a Lianyu Shan, MSc,a Andrew J. Halayko, PhD,b Michael 471Roth, PhD,c Michael Tamm, MD,c, Jamila Chakir, P., d and Abdelilah S. Gounni, PhDa 472Winnipeg, Manitoba, and Quebec City, Quebec, Canada, and Basel, and Switzerland. 473(2013; In press). Neuronal chemorepellent Semaphorin 3E inhibits human airway smooth muscle 474cell proliferation and migration. J Allergy Clin Immunol. 475 Hinz, B., Mastrangelo, D., Iselin, C. E., Chaponnier, C. and Gabbiani, G. (2001). 476Mechanical tension controls granulation tissue contractile activity and myofibroblast 477differentiation. Am J Pathol 159, 1009-20. 478 Ihm, S. H., Youn, H. J., Shin, D. I., Jang, S. W., Park, C. S., Kim, P. J., Kim, H. Y., 479Chang, K., Seung, K. B., Kim, J. H. et al. (2007). Serum carboxy-terminal propeptide of type I 480procollagen (PIP) is a marker of diastolic dysfunction in patients with early type 2 diabetes 481mellitus. International journal of cardiology 122, e36-8. 482 Kokura, K., Kim, H., Shinagawa, T., Khan, M. M., Nomura, T. and Ishii, S. (2003). 483The Ski-binding protein C184M negatively regulates tumor growth factor-beta signaling by 484sequestering the Smad proteins in the cytoplasm. J.Biol.Chem. 278, 20133-20139. 485 Mankoo, B. S., Collins, N. S., Ashby, P., Grigorieva, E., Pevny, L. H., Candia, A., 486Wright, C. V., Rigby, P. W. and Pachnis, V. (1999). Mox2 is a component of the genetic 487hierarchy controlling limb muscle development. Nature 400, 69-73. 488 Mankoo, B. S., Skuntz, S., Harrigan, I., Grigorieva, E., Candia, A., Wright, C. V., 489Arnheiter, H. and Pachnis, V. (2003). The concerted action of Meox homeobox genes is 490required upstream of genetic pathways essential for the formation, patterning and differentiation 491of somites. Development 130, 4655-64. 492 Mollmann, H., Nef, H. M., Kostin, S., von Kalle, C., Pilz, I., Weber, M., Schaper, J., 493Hamm, C. W. and Elsasser, A. (2006). Bone marrow-derived cells contribute to infarct 494remodelling. Cardiovascular research 71, 661-71. 495 Nagata, M., Goto, K., Ehata, S., Kobayashi, N., Saitoh, M., Miyoshi, H., Imamura, 496T., Miyazawa, K. and Miyazono, K. (2006). Nuclear and cytoplasmic c-Ski differently 497modulate cellular functions. Genes Cells 11, 1267-1280. 498 Pelouch, V., Dixon, I. M., Sethi, R. and Dhalla, N. S. (1993). Alteration of collagenous 499protein profile in congestive heart failure secondary to myocardial infarction. Mol.Cell Biochem. 500129, 121-131. 501 Santiago, J. J., Dangerfield, A. L., Rattan, S. G., Bathe, K. L., Cunnington, R. H., 502Raizman, J. E., Bedosky, K. M., Freed, D. H., Kardami, E. and Dixon, I. M. (2010). Cardiac 503fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion 504components in neonatal and adult rat ventricular myofibroblasts. Dev.Dyn. 239, 1573-1584. 505 Serini, G., Bochaton-Piallat, M. L., Ropraz, P., Geinoz, A., Borsi, L., Zardi, L. and 506Gabbiani, G. (1998). The fibronectin domain ED-A is crucial for myofibroblastic phenotype 507induction by transforming growth factor-beta1. J Cell Biol 142, 873-81. 508
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., 509Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J. and Klenk, D. C. (1985). 510Measurement of protein using bicinchoninic acid. Anal.Biochem. 150, 76-85. 511 Sun, Y., Liu, X., Eaton, E. N., Lane, W. S., Lodish, H. F. and Weinberg, R. A. 512(1999). Interaction of the Ski oncoprotein with Smad3 regulates TGF-beta signaling. Mol.Cell 4, 513499-509. 514 Sutrave, P., Copeland, T. D., Showalter, S. D. and Hughes, S. H. (1990a). 515Characterization of chicken c-ski oncogene products expressed by retrovirus vectors. Mol.Cell 516Biol. 10, 3137-3144. 517 Sutrave, P., Kelly, A. M. and Hughes, S. H. (1990b). ski can cause selective growth of 518skeletal muscle in transgenic mice. Genes Dev. 4, 1462-1472. 519 Suzuki, H., Yagi, K., Kondo, M., Kato, M., Miyazono, K. and Miyazawa, K. (2004). 520c-Ski inhibits the TGF-beta signaling pathway through stabilization of inactive Smad complexes 521on Smad-binding elements. Oncogene. 23, 5068-5076. 522 Thayer, P., Balachandran, K., Rathan, S., Yap, C. H., Arjunon, S., Jo, H. and 523Yoganathan, A. P. (2011). The effects of combined cyclic stretch and pressure on the aortic 524valve interstitial cell phenotype. Annals of biomedical engineering 39, 1654-67. 525 Ueki, N. and Hayman, M. J. (2003). Direct interaction of Ski with either Smad3 or 526Smad4 is necessary and sufficient for Ski-mediated repression of transforming growth factor-527beta signaling. J.Biol.Chem. 278, 32489-32492. 528 Valcourt, U., Thuault, S., Pardali, K., Heldin, C. H. and Moustakas, A. (2007). 529Functional role of Meox2 during the epithelial cytostatic response to TGF-beta. Mol Oncol 1, 55-53071. 531 van Amerongen, M. J., Bou-Gharios, G., Popa, E., van Ark, J., Petersen, A. H., van 532Dam, G. M., van Luyn, M. J. and Harmsen, M. C. (2008). Bone marrow-derived 533myofibroblasts contribute functionally to scar formation after myocardial infarction. The Journal 534of pathology 214, 377-86. 535 van Tuyn, J., Atsma, D. E., Winter, E. M., van der Velde-van Dijke, I., Pijnappels, 536D. A., Bax, N. A., Knaan-Shanzer, S., Gittenberger-de Groot, A. C., Poelmann, R. E., van 537der Laarse, A. et al. (2007). Epicardial cells of human adults can undergo an epithelial-to-538mesenchymal transition and obtain characteristics of smooth muscle cells in vitro. Stem cells 25, 539271-8. 540 Wang, J., Chen, H., Seth, A. and McCulloch, C. A. (2003). Mechanical force 541regulation of myofibroblast differentiation in cardiac fibroblasts. Am.J.Physiol Heart 542Circ.Physiol 285, H1871-H1881. 543 Weber, K. T. and Brilla, C. G. (1991). Pathological hypertrophy and cardiac 544interstitium. Fibrosis and renin- angiotensin-aldosterone system. Circulation 83, 1849-1865. 545 Weir, L., Chen, D., Pastore, C., Isner, J. M. and Walsh, K. (1995). Expression of gax, 546a growth arrest homeobox gene, is rapidly down-regulated in the rat carotid artery during the 547proliferative response to balloon injury. J Biol Chem 270, 5457-61. 548 Willems, I. E., Havenith, M. G., De Mey, J. G. and Daemen, M. J. (1994). The alpha-549smooth muscle actin-positive cells in healing human myocardial scars. Am J Pathol 145, 868-75. 550 Xu, W., Angelis, K., Danielpour, D., Haddad, M. M., Bischof, O., Campisi, J., 551Stavnezer, E. and Medrano, E. E. (2000). Ski acts as a co-repressor with Smad2 and Smad3 to 552regulate the response to type beta transforming growth factor. Proc.Natl.Acad.Sci.U.S.A. 97, 5535924-5929. 554
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Zhou, B., von Gise, A., Ma, Q., Hu, Y. W. and Pu, W. T. (2010). Genetic fate mapping 555demonstrates contribution of epicardium-derived cells to the annulus fibrosis of the mammalian 556heart. Developmental biology 338, 251-61. 557
558
Figure Legends 559
Figure 1. The role of Meox1 and Meox2 in cardiac fibroblast-to-myofibroblast 560phenoconversion. (Panel A) Meox1 and Meox2 RNA levels are reduced during fibroblast-to-561myofibroblast differentiation. RNA was harvested from P0, P1 and P2 cells and used for qPCR. 562GAPDH primers served as a control for loading. The data shown were obtained from n = 3 563independent experiments. * = P < 0.005. (Panel B) Primary fibroblasts (P0) and first (P1) and 564second (P2) passage myofibroblasts were isolated, total protein prepared, and Meox2 protein 565expression examined via Western blot using α-tubulin as a loading control. Representative 566Western blots for Meox2 and α-tubulin protein expression are shown above the histograms for 567Meox2 protein expression. The data shown are from n = 3 independent experiments; * P < 0.01 568vs. P0. (Panel C) Cryosections of 4 week post-MI rat heart tissue were stained for Meox2 569(green) and Vimentin (red) with DAPI nuclear stain (blue). Images are representative of n = 3 570hearts. 571
Figure 2. Rat cardiac myofibroblast phenotype is altered by Meox2 but not by Meox1 or 572Meox2 DNA binding mutant over-expression. (Panel A) Meox2 over-expression causes a 573reduction of the myofibroblast phenotype. P1 cardiac myofibroblasts were transduced with Ad-574LacZ (100 MOI) or Ad-FLAG-Meox2 (200 MOI). Non-transduced cells were cultured as an 575additional control. Cells were allowed to grow in the presence of virus for 48 hours before 576harvesting for Western blot analysis. Myofibroblast phenotype was assessed using α-SMA, ED-577A fibronectin and SMemb antibodies with β-tubulin expression used as a loading control. Images 578are representative of n = 4 independent experiments. (Panel B) Histographic representation of 579Western blots in (A). α-SMA, * = P < 0.01 vs. control; ED-A fibronectin, † = P < 0.05 vs. 580control. No significant differences among groups were detected in the SMemb assay data. Data 581were obtained from n = 4 independent experiments. (Panel C) First passage (i.e., P1) 582myofibroblasts were transduced with Ad-LacZ (100 MOI), Ad-FLAG-Meox1 (200 MOI), Ad-583FLAG-Meox2 DBDmt (200 MOI) or left non-transduced for 48 hours. Representative Western 584blots are shown α-SMA, ED-A fibronectin, Smemb and FLAG expression using eEF2 585expression as a loading control. (Panel D) Histographic representation of data in (A). The data 586shown are from n = 7 - 10 independent experiments. 587
Figure 3. Meox2 overexpression induces rat ventricular myofibroblast proliferation. Rat 588ventricular myofibroblasts (passage 3) were infected with Meox2 and LacZ adenoviral vectors 589(50 MOI) and cellular proliferation was investigated by FACS analysis using EdU (Figure 3 590panels A and B) and hemocytometry (Figure 3C and 3D) at 24 h post infection. (p < 0.01, p < 5910.001). In Figure 3 Panel A and Panel B the gate is indicated by the trapezoidal box, and the Meox2 592
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
treated cells show higher incidence of EdU-positive staining. Cell number estimation in Panel C 593reveals a significant increase in Meox2 treatment vs. control which corresponds to the results of the 594EdU detection study. The histographic data are based on three independent experiments in two 595different populations of rat ventricular P3 myofibroblasts. 596
Figure 4. Ski over-expression affects myofibroblast phenotype. (A) ED-A fibronectin is 597decreased in Ski over-expressing cells. P1 cardiac myofibroblasts were infected with either Ad-598LacZ (100 MOI) or Ad-HA-Ski (50, 100 MOI) for 24 hours. Non-transduced cells served as a 599control. Total ED-A fibronectin expression was examined by Western blot using β-tubulin as a 600loading control. (Panel B) Histographic representation of data obtained in (Panel A). The image 601shown is representative of n = 4 independent experiments. *P < 0.01 vs. control; † P < 0.01 vs. 60250 MOI. (Panel C) SMemb is not significantly altered with Ad-HA-Ski transduction. P1 cardiac 603myofibroblasts were infected with either Ad-LacZ (100 MOI) or Ad-HA-Ski (100 MOI) for 48 604hours. Non-infected cells served as a control. Total SMemb expression was examined by 605Western blot analysis using β-tubulin expression as a loading control. (Panel D) Histographic 606representation of data obtained in Panel C. The image shown is representative of n = 3 607independent experiments. 608
Figure 5. Over-expression of Ski upregulates Meox2 mRNA expression. P1 cardiac 609myofibroblasts were either transduced with Ad-LacZ (100 MOI), Ad-HA-Ski (100 MOI) or not 610transduced (control). Cells were serum-starved for 24 hours and then were either left untreated or 611were stimulated with TGF-β1 (10 ng/ml for 24 h). Total RNA was isolated and one-step qPCR 612was performed with Meox1 and Meox2 primers. GAPDH primers were used to control for 613loading. * = P < 0.005 vs. control. The data shown are from n = 4 independent experiments. 614
Figure 6. Increased Zeb2 expression in rat ventricular myofibroblasts can be attenuated by 615Ski overexpression. Primary fibroblasts (P0) and first (P1) and second (P2) passage 616myofibroblasts were isolated, total protein prepared, and Zeb2 protein expression examined via 617Western blot using β-tubulin and α-tubulin as a loading control. (Panel A) Representative 618Western blots for Zeb2 and α-tubulin protein expression. (Panel C) Histographic representation 619of data in Panel A. The data shown are from n = 3 independent experiments; * P < 0.01 vs. P0 ; † 620P < 0.01 vs. P1. (Panel B) First passage (i.e., P1) myofibroblasts were transduced with Ad-LacZ 621(100 MOI), Ad-HA-Ski (100 MOI) or left non-transduced for 48 hours. Total protein was 622isolated followed by Western blot analysis. Representative Western blots for Zeb2 using β-623tubulin as a loading control are shown. (Panel D) Histographic representation of data in Panel B. 624The data shown are from n = 3 independent experiments. * P<0.01 vs. control. 625
Figure 7. Expression of Meox2 and Zeb2 in post-myocardial infarction (MI) cardiac tissues. 626Representative Western blots show cytosolic Meox2 (Panel A and histographic representation 627in Panel B) and Zeb2 (Panel C with histographic representation in Panel D) protein obtained 628from sham-operated control hearts and remnant tissue, as well as tissue from the infarct zone in 62948 hr, 2 week, and 4 week post-myocardial infarction left ventricular samples. 630
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Figure 8. Model of the signaling pathway for Ski modulation of myofibroblast phenotype. 631We have previously demonstrated that Ski over-expression leads to decreased collagen secretion 632in cardiac myofibroblasts. Based on the data generated in the current study, we propose that Ski 633represses expression of the Zeb2 protein through unknown mechanisms (bottom of Figure). 634Inhibition of Zeb2 protein then de-represses Meox2, thereby partially restoring the fibroblastic 635phenotype and decreasing myofibroblastic function (e.g.. collagen type I synthesis/secretion). 636After injury (top segment of Figure) we suggest that cytosolic movement of Ski is causal to 637elevated Zeb2 expression and repression of Meox2, thus facilitating fibroblast to myofibroblast 638phenoconversion. 639
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t
Jour
nal o
f Cel
l Sci
ence
Acc
epte
d m
anus
crip
t